CN111909152A - The preparation method of BTK inhibitor and its intermediate - Google Patents
The preparation method of BTK inhibitor and its intermediate Download PDFInfo
- Publication number
- CN111909152A CN111909152A CN201910382010.9A CN201910382010A CN111909152A CN 111909152 A CN111909152 A CN 111909152A CN 201910382010 A CN201910382010 A CN 201910382010A CN 111909152 A CN111909152 A CN 111909152A
- Authority
- CN
- China
- Prior art keywords
- acid
- solvent
- compound
- ethanol
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及(S)‑7‑(1‑丙烯酰基哌啶‑4‑基)‑2‑(4‑苯氧基苯基)‑4,5,6,7‑四氢吡唑并[1,5‑a]嘧啶‑3‑甲酰胺及其中间体的制备方法。The present invention relates to (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1, 5-a] Pyrimidine-3-carboxamide and the preparation method of its intermediate.
Description
技术领域technical field
本发明涉及(S)-7-(1-丙烯酰基哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺及其中间体的制备方法。The present invention relates to (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1, The preparation method of 5-a]pyrimidine-3-carboxamide and its intermediates.
背景技术Background technique
国际申请WO2014173289披露了一系列可作为布鲁顿氏酪氨酸激酶(Bruton's酪氨酸激酶,BTK)抑制剂的稠合杂环化合物。具体而言,WO2014173289披露了(S)-7-(1-丙烯酰基哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺(在下文亦称为化合物1)International application WO2014173289 discloses a series of fused heterocyclic compounds that can act as Bruton's tyrosine kinase (BTK) inhibitors. Specifically, WO2014173289 discloses (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazole Iso[1,5-a]pyrimidine-3-carboxamide (hereinafter also referred to as compound 1)
化合物1是有效的、特异性的和不可逆的BTK抑制剂。临床前研究数据表明,化合物1可能对抑制B-细胞恶性肿瘤生长具有显著作用。由于对于抑制BTK对EGFR、FGR、FRK、HER2、HER4、ITK、JAK3、LCK和TEC,化合物1显示比依鲁替尼(ibrutinib)更好的选择性,预期在临床上较依鲁替尼更小的副作用。此外,化合物1由于其较弱的ITK抑制,显示出其对利妥昔单抗诱导的抗原依赖性细胞介导的细胞毒性(ADCC)显著小于依鲁替尼,并且因此可在与利妥昔单抗或其他ADCC依赖性抗体组合用于治疗B-细胞恶性肿瘤时提供更好的功效。Compound 1 is a potent, specific and irreversible BTK inhibitor. Data from preclinical studies suggest that Compound 1 may have a significant effect on inhibiting the growth of B-cell malignancies. Compound 1 shows better selectivity than ibrutinib for inhibiting BTK against EGFR, FGR, FRK, HER2, HER4, ITK, JAK3, LCK and TEC and is expected to be more clinically effective than ibrutinib Small side effects. In addition, compound 1 showed significantly less rituximab-induced antigen-dependent cell-mediated cytotoxicity (ADCC) than ibrutinib due to its weaker ITK inhibition, and is therefore comparable to rituximab. Monoclonal antibodies or other ADCC-dependent antibody combinations provide better efficacy when used to treat B-cell malignancies.
WO2018033853披露了一种制备化合物1的方法,该方法利用手性酸拆分剂D-DBTA拆分BG-11A,得到了单一立体构型的中间体BG-11B。WO2018033853披露的方法适合工业化大规模生产,但是关键的手性拆分步骤使用的中间体BG-11A的产率有待提高。WO2018033853 discloses a method for preparing compound 1. The method utilizes a chiral acid resolving agent D-DBTA to resolve BG-11A to obtain an intermediate BG-11B with a single stereoconfiguration. The method disclosed in WO2018033853 is suitable for industrial large-scale production, but the yield of the intermediate BG-11A used in the key chiral resolution step needs to be improved.
发明内容SUMMARY OF THE INVENTION
本发明的发明人发现:通过优化反应参数,特别是通过改善从中间体BG-10合成中间体BG-11A步骤的反应温度,显著地提高了反应产率和产物的纯度。The inventors of the present invention found that by optimizing the reaction parameters, especially by improving the reaction temperature of the step of synthesizing intermediate BG-11A from intermediate BG-10, the reaction yield and product purity were significantly improved.
第一方面,本发明涉及制备化合物1的方法,所述方法包括:使中间体BG-13与丙烯酰基化合物在溶剂中反应,然后加入化合物1的晶种,结晶得到化合物1。In a first aspect, the present invention relates to a method for preparing compound 1, the method comprising: reacting intermediate BG-13 with an acryloyl compound in a solvent, then adding seed crystals of compound 1, and crystallizing to obtain compound 1.
在一些实施方案中,所述丙烯酰基化合物投料当量为0.95-1.3。In some embodiments, the acryloyl compound charge equivalent weight is 0.95-1.3.
在一些实施方案中,所述丙烯酰基化合物选自丙烯酰卤、丙烯酸或丙烯酸酐。在进一步实施方案中,所述丙烯酰基化合物为丙烯酰卤,优选为丙烯酰氯。In some embodiments, the acryloyl compound is selected from acryloyl halide, acrylic acid, or acrylic anhydride. In a further embodiment, the acryloyl compound is an acryloyl halide, preferably an acryloyl chloride.
在一些实施方案中,所述反应进一步在L-(+)-酒石酸和碳酸氢钠的存在下进行。In some embodiments, the reaction is further carried out in the presence of L-(+)-tartaric acid and sodium bicarbonate.
在一些实施方案中,所述溶剂选自非极性溶剂、极性质子溶剂和极性非质子溶剂,或者它们的混合物。合适的极性非质子溶剂,包括但不限于,N-甲基吡咯烷酮、N-甲基吗啉、甲基异丁基酮、甲基乙基酮、四氢呋喃、二氯甲烷、乙酸乙酯、丙酮、N,N-二甲基甲酰胺、乙腈和二甲基亚砜。合适的极性质子溶剂,包括但不限于,水、甲醇、乙醇、正丙醇、异丙醇、正丁醇、异丁醇、叔丁醇、甲酸或乙酸等。合适的非极性溶剂包括但不限于二噁烷、甲苯、己烷、环己烷和乙醚。在进一步实施方案中,所述溶剂为极性非质子溶剂和极性质子溶剂的混合溶剂。优选地,所述溶剂为乙腈和水的混合溶剂。In some embodiments, the solvent is selected from the group consisting of non-polar solvents, polar protic solvents and polar aprotic solvents, or mixtures thereof. Suitable polar aprotic solvents include, but are not limited to, N-methylpyrrolidone, N-methylmorpholine, methyl isobutyl ketone, methyl ethyl ketone, tetrahydrofuran, dichloromethane, ethyl acetate, acetone , N,N-dimethylformamide, acetonitrile and dimethylsulfoxide. Suitable polar protic solvents include, but are not limited to, water, methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, t-butanol, formic acid or acetic acid, and the like. Suitable non-polar solvents include, but are not limited to, dioxane, toluene, hexane, cyclohexane, and diethyl ether. In a further embodiment, the solvent is a mixed solvent of polar aprotic solvent and polar protic solvent. Preferably, the solvent is a mixed solvent of acetonitrile and water.
在一些实施方案中,所述反应在-5至35℃的温度下进行。In some embodiments, the reaction is carried out at a temperature of -5 to 35°C.
在一些实施方案中,本发明所述制备化合物1的方法包括:使中间体BG-13与丙烯酰基化合物在溶剂中反应,至反应完成后,用乙酸乙酯萃取,乙酸乙酯和二氯甲烷进行溶剂交换,然后加入化合物1的晶种,甲基叔丁基醚析晶,得到化合物1。In some embodiments, the method for preparing compound 1 of the present invention comprises: reacting intermediate BG-13 with an acryloyl compound in a solvent, and after the reaction is completed, extracting with ethyl acetate, ethyl acetate and dichloromethane After solvent exchange, seed crystals of compound 1 were added, and methyl tert-butyl ether was crystallized to obtain compound 1.
第二方面,本发明涉及制备中间体BG-13的步骤,其包括:对中间体BG-11D在酸存在的条件下进行水解;或,进一步与拆分剂反应,形成中间体BG-12,其中,所述中间体BG-12在溶剂中用碱脱除拆分剂,得到中间体BG-13,In the second aspect, the present invention relates to a step for preparing intermediate BG-13, which comprises: hydrolyzing intermediate BG-11D in the presence of an acid; or, further reacting with a resolving agent to form intermediate BG-12, Wherein, described intermediate BG-12 removes resolving agent with alkali in solvent, obtains intermediate BG-13,
对水解中使用的酸没有特别限制,可以是常见的有机酸或无机酸。所述无机酸,例如为盐酸、磷酸、二氢磷酸、氢溴酸、硫酸、亚硫酸和硝酸;以及,所述有机酸,例如为苹果酸、马来酸、富马酸、酒石酸、琥珀酸、枸橼酸、乳酸、甲磺酸、对甲苯磺酸、2-羟基乙磺酸、苯甲酸、水杨酸、硬脂酸、链烷酸(诸如乙酸和HOOC-(CH2)n-COOH,其中n选自0-4)等。在一些实施方案中,所述酸是有机酸,例如甲磺酸。在一些实施方案中,所述水解反应在75至100℃的温度进行,优选地在75至85℃的温度进行,更优选优选地在75至80℃的温度进行。The acid used in the hydrolysis is not particularly limited, and may be a common organic acid or inorganic acid. The inorganic acids are, for example, hydrochloric acid, phosphoric acid, dihydrogen phosphoric acid, hydrobromic acid, sulfuric acid, sulfurous acid and nitric acid; and, the organic acids are, for example, malic acid, maleic acid, fumaric acid, tartaric acid, succinic acid , citric acid, lactic acid, methanesulfonic acid, p-toluenesulfonic acid, 2-hydroxyethanesulfonic acid, benzoic acid, salicylic acid, stearic acid, alkanoic acids (such as acetic acid and HOOC-(CH2)n-COOH, wherein n is selected from 0-4) and the like. In some embodiments, the acid is an organic acid, such as methanesulfonic acid. In some embodiments, the hydrolysis reaction is carried out at a temperature of 75 to 100°C, preferably at a temperature of 75 to 85°C, more preferably at a temperature of 75 to 80°C.
在一些实施方案中,对中间体BG-11D在酸存在的条件下进行水解后,进一步用碱调节pH值至11-12。In some embodiments, after hydrolysis of the intermediate BG-11D in the presence of an acid, the pH is further adjusted to 11-12 with a base.
在一些实施方案中,所述拆分剂为酸性拆分剂,例如(+)-酒石酸、(+)-樟脑酸、(+)-樟脑-10-磺酸、L-(+)-甘氨酸、L-(+)-二苯甲酰酒石酸(L-DBTA)等,优选为L-DBTA。In some embodiments, the resolving agent is an acidic resolving agent such as (+)-tartaric acid, (+)-camphoric acid, (+)-camphor-10-sulfonic acid, L-(+)-glycine, L-(+)-dibenzoyltartaric acid (L-DBTA) and the like, preferably L-DBTA.
在一些实施方案中,所述溶剂为选自非极性溶剂、极性质子溶剂和极性非质子溶剂,或者它们的混合物。在进一步的实施方案中,所述溶剂为极性非质子溶剂,选自N-甲基吡咯烷酮、N-甲基吗啉、甲基异丁基酮、甲基乙基酮、四氢呋喃、二氯甲烷、乙酸乙酯、丙酮、N,N-二甲基甲酰胺、乙酸异丙酯、乙腈和二甲基亚砜,或者以上两者或者多者的混合物。在更进一步实施方案中,所述溶剂为乙腈。In some embodiments, the solvent is selected from the group consisting of non-polar solvents, polar protic solvents and polar aprotic solvents, or mixtures thereof. In a further embodiment, the solvent is a polar aprotic solvent selected from N-methylpyrrolidone, N-methylmorpholine, methyl isobutyl ketone, methyl ethyl ketone, tetrahydrofuran, dichloromethane , ethyl acetate, acetone, N,N-dimethylformamide, isopropyl acetate, acetonitrile and dimethyl sulfoxide, or a mixture of two or more of the above. In still further embodiments, the solvent is acetonitrile.
在一些实施方案中,所述碱为碱金属氢氧化物、碱土金属氢氧化物、碱金属碳酸盐、碱金属碳酸氢盐、碱金属碳酸氢盐或碱土金属碳酸氢盐,优选为氢氧化钠、氢氧化钾或碳酸氢钠等。In some embodiments, the base is an alkali metal hydroxide, alkaline earth metal hydroxide, alkali metal carbonate, alkali metal bicarbonate, alkali metal bicarbonate or alkaline earth metal bicarbonate, preferably hydroxide Sodium, potassium hydroxide or sodium bicarbonate, etc.
在一个具体实施方案中,制备BG-13的方法包括:In a specific embodiment, the method of preparing BG-13 comprises:
第三方面,本发明涉及制备BG-11D的步骤,其包括:用拆分剂对中间体BG-11A进行拆分,得到中间体盐BG-11B,In a third aspect, the present invention relates to a step for preparing BG-11D, which comprises: splitting intermediate BG-11A with a resolving agent to obtain intermediate salt BG-11B,
然后使中间体盐BG-11B与碱反应,脱除结合的拆分剂,得到对映异构的中间体BG-11D,Then the intermediate salt BG-11B is reacted with a base to remove the combined resolving agent to obtain an enantiomeric intermediate BG-11D,
在一些实施方案中,所述拆分剂为酸性拆分剂。所述酸性拆分剂选自(+)-酒石酸、(+)-樟脑酸、(+)-樟脑-10-磺酸、D-(+)-甘氨酸、D-(+)-二苯甲酰酒石酸(D-DBTA)等。优选地,所述拆分剂为D-DBTA。In some embodiments, the resolving agent is an acidic resolving agent. The acidic resolving agent is selected from (+)-tartaric acid, (+)-camphoric acid, (+)-camphor-10-sulfonic acid, D-(+)-glycine, D-(+)-dibenzoyl Tartaric acid (D-DBTA), etc. Preferably, the resolving agent is D-DBTA.
在一些实施方案中,所述拆分反应中使用的混合溶剂是乙酸/水/乙醇。在进一步实施方案中,乙酸占所述乙酸/水/乙醇混合溶剂中的比例是13-29%质量比。在一些实施方案中,所述混合溶剂的用量不小于23.1体积。In some embodiments, the mixed solvent used in the resolution reaction is acetic acid/water/ethanol. In a further embodiment, the proportion of acetic acid in the acetic acid/water/ethanol mixed solvent is 13-29% by mass. In some embodiments, the amount of the mixed solvent is not less than 23.1 volumes.
在一些实施方案中,将所述中间体BG-11A在所述混合溶剂中于30至65℃的温度搅拌。In some embodiments, the intermediate BG-11A is stirred in the mixed solvent at a temperature of 30 to 65°C.
在一些实施方案中,所述中间体BG-11A于所述混合溶剂中的溶液与所述拆分剂在30-65℃的温度,优选在50至55℃的温度反应。In some embodiments, the solution of the intermediate BG-11A in the mixed solvent is reacted with the resolving agent at a temperature of 30-65°C, preferably at a temperature of 50-55°C.
在一些实施方案中,所述BG-11A与所述拆分剂(优选为D-DBTA)相继或同时添加。在进一步实施方案中,所述BG-11A与所述拆分剂(优选为D-DBTA)同时添加,以获得稳定的化学拆分性能。在一些实施方案中,所述拆分剂(优选为D-DBTA)的量为0.5-1.45当量。In some embodiments, the BG-11A and the resolving agent (preferably D-DBTA) are added sequentially or simultaneously. In a further embodiment, the BG-11A is added simultaneously with the resolving agent (preferably D-DBTA) to obtain stable chemical resolution performance. In some embodiments, the amount of the resolving agent, preferably D-DBTA, is 0.5-1.45 equivalents.
在一些实施方案中,所述中间体盐BG-11B与碱反应,脱除结合的拆分剂的步骤进一步包括添加额外量的拆分剂以重新形成盐。在进一步实施方案中,用于重新形成盐的拆分剂的量为0.2-0.6当量(相对于1.0当量的BG-11B)。In some embodiments, the intermediate salt BG-11B is reacted with a base, and the step of removing the bound resolving agent further comprises adding an additional amount of resolving agent to reform the salt. In a further embodiment, the amount of resolving agent used to reformulate the salt is 0.2-0.6 equivalents (relative to 1.0 equivalents of BG-11B).
在一些实施方案中,在所述中间体盐BG-11B与碱反应,所述碱为碱金属氢氧化物、碱土金属氢氧化物、碱金属碳酸盐、碱金属碳酸氢盐、碱金属碳酸氢盐或碱土金属碳酸氢盐,优选为氢氧化钠、氢氧化钾或碳酸氢钠等。In some embodiments, the intermediate salt BG-11B is reacted with a base that is an alkali metal hydroxide, alkaline earth metal hydroxide, alkali metal carbonate, alkali metal bicarbonate, alkali metal carbonate The hydrogen salt or alkaline earth metal hydrogen carbonate is preferably sodium hydroxide, potassium hydroxide or sodium hydrogen carbonate or the like.
在一些实施方案中,所述溶剂为选自非极性溶剂、极性质子溶剂和极性非质子溶剂,或者它们的混合物。合适的极性非质子溶剂,包括但不限于,N-甲基吡咯烷酮、N-甲基吗啉、甲基异丁基酮、甲基乙基酮、四氢呋喃、二氯甲烷、乙酸乙酯、丙酮、N,N-二甲基甲酰胺、乙腈和二甲基亚砜。合适的极性质子溶剂,包括但不限于,水、甲醇、乙醇、正丙醇、异丙醇、正丁醇、异丁醇、叔丁醇、甲酸或乙酸等。合适的非极性溶剂,包括但不限于,二噁烷、甲苯、己烷、环己烷和乙醚。在进一步实施方案中,所述溶剂为极性非质子溶剂和极性质子溶剂的混合溶剂。优选地,所述溶剂为乙腈和水的混合溶剂。In some embodiments, the solvent is selected from the group consisting of non-polar solvents, polar protic solvents and polar aprotic solvents, or mixtures thereof. Suitable polar aprotic solvents include, but are not limited to, N-methylpyrrolidone, N-methylmorpholine, methyl isobutyl ketone, methyl ethyl ketone, tetrahydrofuran, dichloromethane, ethyl acetate, acetone , N,N-dimethylformamide, acetonitrile and dimethylsulfoxide. Suitable polar protic solvents include, but are not limited to, water, methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, t-butanol, formic acid or acetic acid, and the like. Suitable non-polar solvents include, but are not limited to, dioxane, toluene, hexane, cyclohexane, and diethyl ether. In a further embodiment, the solvent is a mixed solvent of polar aprotic solvent and polar protic solvent. Preferably, the solvent is a mixed solvent of acetonitrile and water.
在一个具体实施方案中,制备BG-11D的方法包括:In a specific embodiment, the method of making BG-11D comprises:
第四方面,本发明涉及制备中间体BG-11A的步骤,其包括:用酸在升高的温度在溶剂中处理中间体BG-11A,以脱去Boc基团,得到中间体BG-11A,In a fourth aspect, the present invention relates to a step for preparing intermediate BG-11A, comprising: treating intermediate BG-11A in a solvent with an acid at an elevated temperature to remove the Boc group to obtain intermediate BG-11A,
在一些实施方案中,所述酸为无机酸或有机酸,所述无机酸例如为盐酸、磷酸、二氢磷酸、氢溴酸、硫酸、亚硫酸和硝酸;以及所述有机酸例如为苹果酸、马来酸、富马酸、酒石酸、琥珀酸、枸橼酸、乳酸、甲磺酸、对甲苯磺酸、2-羟基乙磺酸、苯甲酸、水杨酸、硬脂酸、链烷酸(诸如乙酸和HOOC-(CH2)n-COOH,其中n选自0-4)等。优选地,所述酸为盐酸。In some embodiments, the acid is an inorganic acid or an organic acid such as hydrochloric acid, phosphoric acid, dihydrogen phosphoric acid, hydrobromic acid, sulfuric acid, sulfurous acid and nitric acid; and the organic acid such as malic acid , maleic acid, fumaric acid, tartaric acid, succinic acid, citric acid, lactic acid, methanesulfonic acid, p-toluenesulfonic acid, 2-hydroxyethanesulfonic acid, benzoic acid, salicylic acid, stearic acid, alkanoic acid (such as acetic acid and HOOC-(CH2)n-COOH, where n is selected from 0-4) and the like. Preferably, the acid is hydrochloric acid.
在一些实施方案中,所述升高的温度为高于室温,低于65℃的温度。在进一步实施方案中,所述升高的温度为40至60℃的温度范围。In some embodiments, the elevated temperature is a temperature above room temperature and below 65°C. In further embodiments, the elevated temperature is in the temperature range of 40 to 60°C.
在一些实施方案中,所述溶剂为非极性溶剂、极性质子溶剂和极性非质子溶剂,或者它们的混合物。合适的极性非质子溶剂包括但不限于N-甲基吡咯烷酮、N-甲基吗啉、甲基异丁基酮、甲基乙基酮、四氢呋喃、二氯甲烷、乙酸乙酯、丙酮、N,N-二甲基甲酰胺、乙腈和二甲基亚砜。合适的极性质子溶剂包括但不限于水、甲醇、乙醇、正丙醇、异丙醇、正丁醇、异丁醇、叔丁醇、甲酸或乙酸等。合适的非极性溶剂包括但不限于二噁烷、甲苯、己烷、环己烷和乙醚。优选地,所述溶剂为乙醇。In some embodiments, the solvent is a non-polar solvent, polar protic solvent, polar aprotic solvent, or a mixture thereof. Suitable polar aprotic solvents include, but are not limited to, N-methylpyrrolidone, N-methylmorpholine, methyl isobutyl ketone, methyl ethyl ketone, tetrahydrofuran, dichloromethane, ethyl acetate, acetone, N , N-dimethylformamide, acetonitrile and dimethyl sulfoxide. Suitable polar protic solvents include, but are not limited to, water, methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, t-butanol, formic acid or acetic acid, and the like. Suitable non-polar solvents include, but are not limited to, dioxane, toluene, hexane, cyclohexane, and diethyl ether. Preferably, the solvent is ethanol.
在一些实施方案中,所述溶剂(优选为乙醇)的量为5.0-8.0X(质量)。In some embodiments, the amount of the solvent (preferably ethanol) is 5.0-8.0X (mass).
在一些实施方案中,所述脱保护反应进行不超过72小时。In some embodiments, the deprotection reaction is performed for no more than 72 hours.
在一些实施方案中,所述制备中间体BG-11A的方法进一步包括:在脱保护反应之后,在20至75℃的温度调节pH值,优选在50至65℃的温度调节pH值。在进一步实施方案中,所述pH值不低于11.5,优选为12.5-13.5的范围。在更进一步实施方案中,pH值是通过增加碱性溶液调节的,例如添加氢氧化钠水溶液。In some embodiments, the method of preparing the intermediate BG-11A further comprises: after the deprotection reaction, adjusting the pH at a temperature of 20 to 75°C, preferably at a temperature of 50 to 65°C. In a further embodiment, the pH value is not lower than 11.5, preferably in the range of 12.5-13.5. In still further embodiments, the pH is adjusted by adding an alkaline solution, such as the addition of aqueous sodium hydroxide.
在一具体实施方案中,制备BG-11A的方法包括:In a specific embodiment, the method of making BG-11A comprises:
实施例Example
以下反应方案详细地描述了从中间体BG-10开始,制备化合物1的方案。The following reaction scheme details the preparation of compound 1 starting from intermediate BG-10.
反应方案reaction scheme
本发明的方法尤其适于以高品质和高收率可重复地以商业规模制备化合物1;而且通过优化或改进合成工艺,本发明的方法能够进一步提高每步的反应收率或纯度,以更经济或更环保的方式生成最终目标化合物。The method of the present invention is particularly suitable for the reproducible preparation of compound 1 on a commercial scale with high quality and high yield; and by optimizing or improving the synthesis process, the method of the present invention can further improve the reaction yield or purity of each step, so as to improve the An economical or more environmentally friendly way to generate the final target compound.
例如,从由中间体BG-10合成BG-11A的步骤中,采用更环保的乙醇作为溶剂替换原来的二氯甲烷;在升高的温度下进行脱保护反应,进一步提高了反应产物的纯度和/或产率得到了明显提高(例如高至97.6%);而且,进一步降低了下游步骤的工艺复杂性。For example, in the step of synthesizing BG-11A from the intermediate BG-10, more environmentally friendly ethanol is used as the solvent to replace the original methylene chloride; the deprotection reaction is carried out at an elevated temperature, which further improves the purity and purity of the reaction product. /or the yield is significantly improved (eg up to 97.6%); moreover, the process complexity of the downstream steps is further reduced.
又例如,在由中间体BG-11A合成BG-11D的步骤中,所使用的溶剂量减少为约50%。同时加入中间体BG-11A和拆分剂D-DBTA,获得了一致的化学拆分性能;并且实现了稳定的化学拆分性能和高的手性纯度;并且整个制造周期时间也得到了减少,进而提高了制造效率。As another example, in the step of synthesizing BG-11D from intermediate BG-11A, the amount of solvent used is reduced to about 50%. At the same time, the intermediate BG-11A and the resolving agent D-DBTA were added, and consistent chemical resolution performance was obtained; and stable chemical resolution performance and high chiral purity were achieved; and the entire manufacturing cycle time was also reduced, Thus, the manufacturing efficiency is improved.
又例如,在由中间体BG-11D合成BG-13的步骤中,通过加入溶剂乙腈直接进行相分离,从而优化了后处理步骤;并且BG-13直接分离为游离碱形式,而非L-DBTA盐形式。而且所添加的甲磺酸能够通过简单的后处理就能够除去。该步骤还能够减少一些杂质的生成。For another example, in the step of synthesizing BG-13 from the intermediate BG-11D, the phase separation is directly carried out by adding the solvent acetonitrile, thereby optimizing the post-processing steps; and BG-13 is directly separated into the free base form, rather than L-DBTA salt form. Furthermore, the added methanesulfonic acid can be removed by a simple post-treatment. This step can also reduce the generation of some impurities.
再例如,在由中间体BG-13合成化合物1的步骤中,特别是在后处理中通过添加晶种优化了结晶工艺,避免了结晶过程出现结块,进而提高了最终产品的质量。For another example, in the step of synthesizing compound 1 from the intermediate BG-13, especially in the post-treatment, the crystallization process is optimized by adding seed crystals, so as to avoid agglomeration during the crystallization process, thereby improving the quality of the final product.
以下实施例用于示例性说明本发明,但并非用于限制本发明的范围。The following examples are intended to illustrate the present invention, but not to limit the scope of the present invention.
实施例1:合成BG-11AExample 1: Synthesis of BG-11A
实施例1AExample 1A
将化合物BG-10(20g,1.0X)悬浮在乙醇(8.0X)中,然后加入约20%盐酸乙醇溶液。将反应混合物加热至40℃,然后搅拌5小时至反应完成。将反应混合物浓缩,然后加入另外的乙醇和水。在温度20℃条件下,在1小时的时间内,用氢氧化钠水溶液调节pH值至13.2。对混合物进行冷却并且离心分离。所获得的湿滤饼用乙醇/水的混合溶剂洗涤,然后真空干燥,得到化合物15.6g BG-11A(纯度:99.05%,产率:96.6%)。Compound BG-10 (20 g, 1.0X) was suspended in ethanol (8.0X), then about 20% hydrochloric acid in ethanol was added. The reaction mixture was heated to 40°C and stirred for 5 hours until the reaction was complete. The reaction mixture was concentrated, then additional ethanol and water were added. At a temperature of 20°C, the pH was adjusted to 13.2 with an aqueous sodium hydroxide solution over a period of 1 hour. The mixture was cooled and centrifuged. The obtained wet cake was washed with a mixed solvent of ethanol/water, and then vacuum-dried to obtain compound 15.6 g of BG-11A (purity: 99.05%, yield: 96.6%).
实施例1BExample 1B
将化合物BG-10(20g,1.0X)悬浮在乙醇(6.5X)中,然后加入约20%盐酸乙醇溶液。将反应混合物加热至60℃,然后搅拌72小时至反应完成。将反应混合物浓缩,然后加入另外的乙醇和水。在温度50℃条件下,在24小时的时间内,用氢氧化钠水溶液调节pH值至13.0。对混合物进行冷却并且离心分离,然后在乙醇和水中打浆。所获得的湿滤饼用乙醇/水的混合溶剂洗涤,然后真空干燥,得到化合物16.5g BG-11A(纯度:99.13%,产率:95.2%)。Compound BG-10 (20 g, 1.0X) was suspended in ethanol (6.5X), then about 20% hydrochloric acid in ethanol was added. The reaction mixture was heated to 60°C and then stirred for 72 hours until the reaction was complete. The reaction mixture was concentrated, then additional ethanol and water were added. At a temperature of 50°C, the pH was adjusted to 13.0 with an aqueous sodium hydroxide solution over a period of 24 hours. The mixture was cooled and centrifuged, then slurried in ethanol and water. The obtained wet cake was washed with a mixed solvent of ethanol/water, and then vacuum-dried to obtain compound 16.5 g of BG-11A (purity: 99.13%, yield: 95.2%).
实施例2:合成BG-11BExample 2: Synthesis of BG-11B
实施例2AExample 2A
将BG-11A(30g,1.0X,1.0当量)溶于乙醇/水/乙酸的混合物(14.7X,乙酸:23%)中。将所获得的溶液部分转移至反应容器中。再将另外的乙醇/水/乙酸的混合溶剂(3.6X,乙酸:24%)添加至反应容器中。将反应溶液加热至55℃。然后将D-DBTA(1.0当量)溶于乙醇/水/乙酸的混合物(4.8X,乙酸:23%)中,然后将所获得的D-DBTA溶液部分添加至反应容器中,接着加入BG-11B的晶种。一起加入剩余的BG-11A溶液和D-DBTA溶液。将反应混合物在55℃搅拌4小时。然后将混合物冷却,以待结晶。离心收集固体,用乙醇/水/乙酸的混合物、乙醇连续洗涤,接着真空干燥,获得28.31g BG-11B(纯度:99.81%,手性纯度:90.8%,产率:49.2%)。BG-11A (30 g, 1.0X, 1.0 equiv) was dissolved in a mixture of ethanol/water/acetic acid (14.7X, acetic acid: 23%). The obtained solution was partially transferred to the reaction vessel. Additional mixed solvent of ethanol/water/acetic acid (3.6X, acetic acid: 24%) was added to the reaction vessel. The reaction solution was heated to 55°C. D-DBTA (1.0 equiv) was then dissolved in a mixture of ethanol/water/acetic acid (4.8X, acetic acid: 23%) and the resulting D-DBTA solution was partially added to the reaction vessel followed by BG-11B seeds. Add the remaining BG-11A solution and D-DBTA solution together. The reaction mixture was stirred at 55°C for 4 hours. The mixture was then cooled to allow crystallization. The solid was collected by centrifugation, washed successively with a mixture of ethanol/water/acetic acid, ethanol, and then vacuum dried to obtain 28.31 g of BG-11B (purity: 99.81%, chiral purity: 90.8%, yield: 49.2%).
实施例2B:Example 2B:
将BG-11A(30g,1.0X,1.0当量)溶于乙醇/水/乙酸的混合物(17.2X,乙酸:23%)中。将所获得的溶液部分转移至反应容器中。再将另外的乙醇/水/乙酸的混合溶剂(4.2X,乙酸:24%)添加至反应容器中。将反应溶液加热至65℃。然后将D-DBTA(1.0当量)溶于乙醇/水/乙酸的混合物(5.7X,乙酸:23%)中,然后将所获得的D-DBTA溶液部分添加至反应容器中,接着加入BG-11B晶体。一起加入剩余的BG-11A溶液和D-DBTA溶液。将反应混合物在65℃搅拌6小时。然后将混合物冷却,以待结晶。离心收集固体,用乙醇/水/乙酸的混合物、乙醇连续洗涤,接着真空干燥,获得22.5g BG-11B(纯度:99.23%,手性纯度:94.1%,产率:39.1%)。BG-11A (30 g, 1.0X, 1.0 equiv) was dissolved in a mixture of ethanol/water/acetic acid (17.2X, acetic acid: 23%). The obtained solution was partially transferred to the reaction vessel. Additional mixed solvent of ethanol/water/acetic acid (4.2X, acetic acid: 24%) was added to the reaction vessel. The reaction solution was heated to 65°C. D-DBTA (1.0 equiv.) was then dissolved in a mixture of ethanol/water/acetic acid (5.7X, acetic acid: 23%) and the resulting D-DBTA solution was partially added to the reaction vessel followed by BG-11B crystal. Add the remaining BG-11A solution and D-DBTA solution together. The reaction mixture was stirred at 65°C for 6 hours. The mixture was then cooled to allow crystallization. The solid was collected by centrifugation, washed successively with a mixture of ethanol/water/acetic acid, ethanol, and then vacuum dried to obtain 22.5 g of BG-11B (purity: 99.23%, chiral purity: 94.1%, yield: 39.1%).
实施例2CExample 2C
将BG-11A(30g,1.0X,1.0当量)溶于乙醇/水/乙酸的混合物(17.2X,乙酸:23%)中。将所获得的溶液部分转移至反应容器中。将另外的乙醇/水/乙酸的混合溶剂(4.2X,乙酸:24%)加至反应容器中。将反应溶液加热至55℃。将D-DBTA(1.45当量)溶于乙醇/水/乙酸的混合溶液(5.7X,乙酸:23%)中,然后将所获得的D-DBTA溶液部分添加至反应容器中,接着加入BG-11B晶体。一起加入剩余的BG-11A溶液和D-DBTA溶液。将反应混合物在55℃搅拌4小时。然后将混合物冷却,以待结晶。离心收集固体,用乙醇/水/乙酸的混合物、乙醇连续洗涤,接着真空干燥,获得28.9g BG-11B(纯度:99.79%,手性纯度:91.3%,产率:50.8%)。BG-11A (30 g, 1.0X, 1.0 equiv) was dissolved in a mixture of ethanol/water/acetic acid (17.2X, acetic acid: 23%). The obtained solution was partially transferred to the reaction vessel. Additional mixed solvent of ethanol/water/acetic acid (4.2X, acetic acid: 24%) was added to the reaction vessel. The reaction solution was heated to 55°C. D-DBTA (1.45 equiv) was dissolved in a mixed solution of ethanol/water/acetic acid (5.7X, acetic acid: 23%), then the obtained D-DBTA solution was partially added to the reaction vessel, followed by BG-11B crystal. Add the remaining BG-11A solution and D-DBTA solution together. The reaction mixture was stirred at 55°C for 4 hours. The mixture was then cooled to allow crystallization. The solid was collected by centrifugation, washed successively with a mixture of ethanol/water/acetic acid, ethanol, and then vacuum dried to obtain 28.9 g of BG-11B (purity: 99.79%, chiral purity: 91.3%, yield: 50.8%).
实施例3:合成BG-11DExample 3: Synthesis of BG-11D
实施例3A-1,第一次拆分:将BG-11A(30.0g,1.0X,1.0当量)溶于乙醇/水/乙酸的混合物(17.0X,乙酸:23.6%)中。将所获得的溶液部分转移至反应容器中。再将另外的乙醇/水/乙酸的混合溶剂(4.2X,乙酸:24.0%)添加反应容器中。将反应器中溶液加热至55℃。然后将D-DBTA(1.0当量)溶于乙醇/水/乙酸的混合物(5.6X,乙酸:23.4%),然后将所获得的D-DBTA溶液部分加至反应容器中,接着加入BG-11B的晶种。将剩余的D-DBTA溶液和BG-11A溶液加入到反应釜中,应混合物在55℃搅拌4小时。然后将混合物冷却,以待晶体完全析出。离心收集固体,用乙醇/水/乙酸的混合物、乙醇各1.6X连续洗涤,接着真空干燥,获得27.3g BG-11B(手性纯度:91.7%,产率:48.0%)。 Example 3A-1, first resolution: BG-11A (30.0 g, 1.0X, 1.0 equiv) was dissolved in a mixture of ethanol/water/acetic acid (17.0X, acetic acid: 23.6%). The obtained solution was partially transferred to the reaction vessel. Additional mixed solvent of ethanol/water/acetic acid (4.2X, acetic acid: 24.0%) was added to the reaction vessel. The solution in the reactor was heated to 55°C. D-DBTA (1.0 equiv.) was then dissolved in a mixture of ethanol/water/acetic acid (5.6X, acetic acid: 23.4%), and the resulting D-DBTA solution was partially added to the reaction vessel, followed by the addition of BG-11B seeds. The remaining D-DBTA solution and BG-11A solution were added to the reaction kettle, and the mixture was stirred at 55°C for 4 hours. The mixture was then cooled to allow complete precipitation of crystals. The solid was collected by centrifugation, washed successively with a mixture of ethanol/water/acetic acid, 1.6X each of ethanol, followed by vacuum drying to obtain 27.3 g of BG-11B (chiral purity: 91.7%, yield: 48.0%).
实施例3B-1,第二次拆分:将BG-11B(20.0g,1.0X,1.0当量)悬浮在乙醇和水中,接着加入氢氧化钾(1.7当量)水溶液。将混合物加热,然后用乙酸和BG-11B晶种处理析出晶体。加入另外的乙酸(1.65X)溶解晶体。滴加D-DBTA(0.4当量)的乙醇/水/乙酸混合溶剂(3.2X,乙酸:11.0%)溶液,接着冷却结晶。离心收集固体,用乙醇/水/乙酸的混合物、乙醇连续洗涤,接着真空干燥,获得16.4g BG-11B(手性纯度:97.4%,产率:81.3%)。 Example 3B-1, Second Resolution: BG-11B (20.0 g, 1.0X, 1.0 equiv) was suspended in ethanol and water followed by the addition of aqueous potassium hydroxide (1.7 equiv). The mixture was heated and then treated with acetic acid and BG-11B seeds to precipitate crystals. Additional acetic acid (1.65X) was added to dissolve the crystals. A solution of D-DBTA (0.4 equiv.) in a mixed solvent of ethanol/water/acetic acid (3.2X, acetic acid: 11.0%) was added dropwise, followed by cooling to crystallize. The solid was collected by centrifugation, washed successively with a mixture of ethanol/water/acetic acid, ethanol, and then vacuum dried to obtain 16.4 g of BG-11B (chiral purity: 97.4%, yield: 81.3%).
实施例3B-2,游离:将BG-11B(30.0g,1.0X,1.0当量)溶于乙腈(4.2X)和水(9.0X)中,接着加入氢氧化钠(30%水溶液,5.0当量)溶液,析出固体。离心收集析出的固体,用水洗涤,接着真空干燥,得到15.5g化合物BG-11D(手性纯度:98.7%,HPLC纯度:99.6%,产率:96.0%)。 Example 3B-2, free: BG-11B (30.0 g, 1.0X, 1.0 equiv) was dissolved in acetonitrile (4.2X) and water (9.0X) followed by sodium hydroxide (30% aqueous solution, 5.0 equiv) solution, a solid precipitated out. The precipitated solid was collected by centrifugation, washed with water, and then dried in vacuo to obtain 15.5 g of compound BG-11D (chiral purity: 98.7%, HPLC purity: 99.6%, yield: 96.0%).
实施例4:合成BG-13Example 4: Synthesis of BG-13
实施例4A:Example 4A:
将化合物BG-11D(20g,1.0X,1.0当量)加至甲磺酸(19.3当量)和水(1.7当量)中。将反应混合物加热至80℃,并且搅拌直至反应完成。然后将混合物冷却,接着加入额外的水和乙腈(4.0X)。在20℃滴加氢氧化钠水溶液,接着加热至50℃。用额外的氢氧化钠水溶液调节pH值至12。收集有机层,接着加入乙酸异丙酯(2.6X),接着用盐水洗涤。将晶种加至所获得的有机层中,然后加入乙酸异丙酯进行溶剂交换。加入甲基叔丁基醚,然后冷却结晶。离心收集固体,用甲基叔丁基醚洗涤,然后真空干燥,得到18.29g粗制的BG-13(纯度:98.73%,产率:87.2%)。Compound BG-11D (20 g, 1.0X, 1.0 equiv) was added to methanesulfonic acid (19.3 equiv) and water (1.7 equiv). The reaction mixture was heated to 80°C and stirred until the reaction was complete. The mixture was then cooled, followed by addition of additional water and acetonitrile (4.0X). Aqueous sodium hydroxide solution was added dropwise at 20°C, followed by heating to 50°C. Adjust pH to 12 with additional aqueous sodium hydroxide solution. The organic layer was collected, followed by the addition of isopropyl acetate (2.6X), followed by a brine wash. Seed crystals were added to the obtained organic layer, followed by addition of isopropyl acetate for solvent exchange. Methyl tert-butyl ether was added, followed by cooling to crystallize. The solid was collected by centrifugation, washed with methyl tert-butyl ether, and then dried in vacuo to obtain 18.29 g of crude BG-13 (purity: 98.73%, yield: 87.2%).
实施例4B:Example 4B:
将化合物BG-11D(20g,1.0X,1.0当量)加至甲磺酸(18.0当量)和水(1.0当量)中。将反应混合物加热至80℃,并且搅拌直至反应完成。然后将混合物冷却,接着加入额外的水和乙腈(4.0X)。在20℃滴加氢氧化钠水溶液,接着加热至50℃。用额外的氢氧化钠水溶液调节pH值至11-12。收集有机层,接着加入乙酸异丙酯(2.6X),接着用盐水洗涤。将晶种加至所获得的有机层中,然后加入乙酸异丙酯进行溶剂交换。加入甲基叔丁基醚,然后冷却结晶。离心收集固体,用甲基叔丁基醚洗涤,然后真空干燥,得到18.7g粗制的BG-13(纯度:98.69%,产率:87.8%)。Compound BG-11D (20 g, 1.0X, 1.0 equiv) was added to methanesulfonic acid (18.0 equiv) and water (1.0 equiv). The reaction mixture was heated to 80°C and stirred until the reaction was complete. The mixture was then cooled, followed by addition of additional water and acetonitrile (4.0X). Aqueous sodium hydroxide solution was added dropwise at 20°C, followed by heating to 50°C. Adjust pH to 11-12 with additional aqueous sodium hydroxide solution. The organic layer was collected, followed by the addition of isopropyl acetate (2.6X), followed by a brine wash. Seed crystals were added to the obtained organic layer, followed by addition of isopropyl acetate for solvent exchange. Methyl tert-butyl ether was added, followed by cooling to crystallize. The solid was collected by centrifugation, washed with methyl tert-butyl ether, and then dried in vacuo to obtain 18.7 g of crude BG-13 (purity: 98.69%, yield: 87.8%).
实施例4C:Example 4C:
将化合物BG-11D(20g,1.0X,1.0当量)加至甲磺酸(18.0当量)和水(1.7当量)中。将反应混合物加热至75℃,并且搅拌直至反应完成。然后将混合物冷却,接着加入额外的水和乙腈(3.7X)。用另外的氢氧化钠水溶液在低于50℃的温度条件下调节pH值至11-12。将混合物的温度调节至50℃。收集有机层,接着加入乙酸异丙酯(2.6X),用盐水洗涤。将晶种加至所获得的有机层中,然后加入乙酸异丙酯进行溶剂交换。加入甲基叔丁基醚,然后冷却结晶。离心收集固体,用甲基叔丁基醚洗涤,然后真空干燥,得到17.63g粗制的BG-13(纯度:98.93%,产率:81.9%)。Compound BG-11D (20 g, 1.0X, 1.0 equiv) was added to methanesulfonic acid (18.0 equiv) and water (1.7 equiv). The reaction mixture was heated to 75°C and stirred until the reaction was complete. The mixture was then cooled, followed by addition of additional water and acetonitrile (3.7X). The pH was adjusted to 11-12 with additional aqueous sodium hydroxide solution at a temperature below 50°C. The temperature of the mixture was adjusted to 50°C. The organic layer was collected, followed by the addition of isopropyl acetate (2.6X) and washed with brine. Seed crystals were added to the obtained organic layer, followed by addition of isopropyl acetate for solvent exchange. Methyl tert-butyl ether was added, followed by cooling to crystallize. The solid was collected by centrifugation, washed with methyl tert-butyl ether, and then dried in vacuo to obtain 17.63 g of crude BG-13 (purity: 98.93%, yield: 81.9%).
实施例4D:Example 4D:
将化合物BG-11D(400g)加至甲磺酸(1720g)和水(30.4g)中。将反应混合物加热至83℃,并且搅拌直至反应完成。将反应溶液分份,采样107.5g(基于20g BG-11D,X=20g,1当量)用于以下步骤。加入额外的水和乙腈(3.0X)。用另外的氢氧化钠水溶液在35℃的温度调节pH值至12。混合物的温度调节至50℃。收集有机层,接着加入乙酸异丙酯(3.2X),用盐水洗涤。将晶种加至所获得的有机层中,然后加入乙酸异丙酯进行溶剂交换。加入甲基叔丁基醚,然后冷却结晶。离心收集固体,用甲基叔丁基醚洗涤,然后真空干燥,得到19g粗制的BG-13(纯度:98.95%,产率:89.5%)。Compound BG-11D (400 g) was added to methanesulfonic acid (1720 g) and water (30.4 g). The reaction mixture was heated to 83°C and stirred until the reaction was complete. The reaction solution was aliquoted and 107.5 g (based on 20 g BG-11D, X=20 g, 1 equiv) were sampled for the following steps. Additional water and acetonitrile (3.0X) were added. The pH was adjusted to 12 with additional aqueous sodium hydroxide solution at a temperature of 35°C. The temperature of the mixture was adjusted to 50°C. The organic layers were collected, followed by the addition of isopropyl acetate (3.2X) and washed with brine. Seed crystals were added to the obtained organic layer, followed by addition of isopropyl acetate for solvent exchange. Methyl tert-butyl ether was added, followed by cooling to crystallize. The solid was collected by centrifugation, washed with methyl tert-butyl ether, and then dried in vacuo to obtain 19 g of crude BG-13 (purity: 98.95%, yield: 89.5%).
实施例4E:Example 4E:
实施例4E-1:将化合物BG-11D(20g,1.0X,1.0当量)加至甲磺酸(16.6当量)和水(1.7当量)中。将反应混合物加热至80℃,并且搅拌直至反应完成。然后将混合物冷却,接着加入乙腈(5.0X体积)。在20℃滴加氢氧化钠水溶液(20%),接着加热至50℃。用额外的氢氧化钠水溶液(20%)调节pH值至11-12。收集有机层,接着加入乙酸异丙酯(2.6X),接着用盐水洗涤。将晶种加至所获得的有机层中,然后加入乙酸异丙酯进行溶剂交换。加入甲基叔丁基醚,然后冷却结晶。离心收集固体,用甲基叔丁基醚洗涤,然后真空干燥,得到18.8g的BG-13粗品(产率:89%)。 Example 4E-1: Compound BG-11D (20 g, 1.0X, 1.0 equiv) was added to methanesulfonic acid (16.6 equiv) and water (1.7 equiv). The reaction mixture was heated to 80°C and stirred until the reaction was complete. The mixture was then cooled and acetonitrile (5.0X vol) was added. Aqueous sodium hydroxide solution (20%) was added dropwise at 20°C, followed by heating to 50°C. The pH was adjusted to 11-12 with additional aqueous sodium hydroxide (20%). The organic layer was collected, followed by the addition of isopropyl acetate (2.6X), followed by a brine wash. Seed crystals were added to the obtained organic layer, followed by addition of isopropyl acetate for solvent exchange. Methyl tert-butyl ether was added, followed by cooling to crystallize. The solid was collected by centrifugation, washed with methyl tert-butyl ether, and then dried in vacuo to obtain 18.8 g of crude BG-13 (yield: 89%).
实施例4E-2:将BG-13粗品(20g)溶于甲醇(6倍质量)和水(4倍质量)中,加热至45℃,接着加入L-DBTA(0.57当量)的甲醇/水溶液。将混合物冷却,以待结晶。离心收集析出的固体,然后用水洗涤,得到BG-12。 Example 4E-2: Crude BG-13 (20 g) was dissolved in methanol (6 times mass) and water (4 times mass), heated to 45°C, followed by addition of L-DBTA (0.57 equiv) in methanol/water solution. The mixture was cooled to allow crystallization. The precipitated solid was collected by centrifugation, and then washed with water to obtain BG-12.
实施例4E-3:将BG-12(65.7g)溶于乙腈和水中,接着加入氢氧化钠水溶液和乙酸异丙酯。收集有机层,然后用盐水洗涤,并且浓缩。加入BG-13的晶种,并且浓缩,然后添加乙酸异丙酯,并且再次蒸馏。将甲基叔丁基醚加至残余物中,然后冷却结晶。离心收集固体,用甲基叔丁基醚洗涤,然后真空干燥,得到BG-13纯品(手性纯度:99.6%,HPLC纯度99.7%,产率:93.4%)。 Example 4E-3: BG-12 (65.7 g) was dissolved in acetonitrile and water, followed by the addition of aqueous sodium hydroxide and isopropyl acetate. The organic layer was collected, then washed with brine, and concentrated. Seed crystals of BG-13 were added and concentrated, then isopropyl acetate was added and distilled again. Methyl tert-butyl ether was added to the residue, which was then crystallized by cooling. The solid was collected by centrifugation, washed with methyl tert-butyl ether, and then dried under vacuum to obtain pure BG-13 (chiral purity: 99.6%, HPLC purity: 99.7%, yield: 93.4%).
实施例5:合成化合物1Example 5: Synthesis of Compound 1
实施例5A:Example 5A:
将化合物BG-13(30g)溶于乙腈和水的混合物中,接着加入L-酒石酸和碳酸氢钠。将混合物冷却,接着加入丙烯酰氯(6.84g)。将溶液在-5℃搅拌,直至反应完成,接着加入乙酸乙酯并且分离。收集有机层,水层再次添加乙酸乙酯萃取。合并有机层,盐水洗涤,接着加入二丁基羟基甲苯(1%)。连续加入乙酸乙酯和二氯甲烷进行溶剂交换,接着加入二丁基羟基甲苯(2%)。Compound BG-13 (30 g) was dissolved in a mixture of acetonitrile and water, followed by addition of L-tartaric acid and sodium bicarbonate. The mixture was cooled and acryloyl chloride (6.84 g) was added. The solution was stirred at -5°C until the reaction was complete, then ethyl acetate was added and separated. The organic layer was collected, and the aqueous layer was extracted with ethyl acetate again. The organic layers were combined, washed with brine, followed by the addition of dibutylhydroxytoluene (1%). Ethyl acetate and dichloromethane were added successively for solvent exchange, followed by dibutylhydroxytoluene (2%).
将溶液分份,取72.2g(16.94g化合物1)用于以下步骤。将所获得的溶液经硅胶过滤(0.67X,X基于BG-13的量)。对溶液进行浓缩,接着加入乙酸乙酯,并且浓缩,加入化合物1晶种,保温结晶。继续浓缩,然后加入甲基叔丁基醚使晶体进一步析出。离心收集固体,用甲基叔丁基醚洗涤,然后真空干燥,得到14.31g粗制的化合物1(纯度:99.84%,产率:83.7%)。The solution was portioned and 72.2 g (16.94 g of Compound 1) were used in the following steps. The resulting solution was filtered through silica gel (0.67X, X based on the amount of BG-13). The solution was concentrated, followed by the addition of ethyl acetate, followed by concentration, seed crystals of compound 1 were added, and crystallization was maintained. Concentration was continued, and then methyl tert-butyl ether was added to further precipitate crystals. The solid was collected by centrifugation, washed with methyl tert-butyl ether, and then dried in vacuo to obtain 14.31 g of crude compound 1 (purity: 99.84%, yield: 83.7%).
实施例5B:Example 5B:
将化合物BG-13(30g)溶于乙腈和水的混合物中,接着加入L-(+)-酒石酸和碳酸氢钠。将混合物冷却,接着加入丙烯酰氯(6.63g)。将溶液在5℃搅拌,直至反应完成,接着加入乙酸乙酯并且分离。收集有机层,水层再次添加乙酸乙酯萃取。合并有机层,用盐水洗涤。Compound BG-13 (30 g) was dissolved in a mixture of acetonitrile and water, followed by the addition of L-(+)-tartaric acid and sodium bicarbonate. The mixture was cooled and acryloyl chloride (6.63 g) was added. The solution was stirred at 5°C until the reaction was complete, then ethyl acetate was added and separated. The organic layer was collected, and the aqueous layer was extracted with ethyl acetate again. The organic layers were combined and washed with brine.
将有机溶液平均分为两份,取一半的有机相(以下表述基于15g BG-13,X=15g)用于以下步骤。连续加入乙酸乙酯和二氯甲烷进行溶剂交换,接着加入二丁基羟基甲苯(1%)。将所获得溶液经硅胶(1.33X)过滤,并且浓缩,接着经硅藻土垫转移至干净的容器中。对溶液进行浓缩,接着加入乙酸乙酯,并且浓缩,加入化合物1晶种,保温搅拌以进行结晶。离心收集固体,用甲基叔丁基醚洗涤,然后真空干燥,得到14.20g粗制的化合物1(纯度:99.75%,产率:83.7%)。The organic solution was equally divided into two parts, and half of the organic phase (the following expression was based on 15 g BG-13, X=15 g) was used in the following steps. Ethyl acetate and dichloromethane were added successively for solvent exchange, followed by dibutylhydroxytoluene (1%). The resulting solution was filtered through silica gel (1.33X) and concentrated, then transferred to a clean vessel through a pad of celite. The solution was concentrated, then ethyl acetate was added, and concentrated, compound 1 seed crystals were added, and the mixture was kept stirring for crystallization. The solid was collected by centrifugation, washed with methyl tert-butyl ether, and then dried in vacuo to obtain 14.20 g of crude compound 1 (purity: 99.75%, yield: 83.7%).
上述某些实施方案的实例和说明应认为是阐述性的,而不应认作是限制由权利要求所限定的本发明。可容易理解的是,可利用上述特征的多种变化和组合而不脱离如权利要求所述的本发明。全部这些变化旨在包括于本发明的范围内。引用的全部参考文献通过引用以其整体并入本申请。The above examples and descriptions of certain embodiments are to be considered illustrative and not to be considered limiting of the invention as defined by the claims. It will be readily understood that various variations and combinations of the above features may be utilized without departing from the invention as claimed. All such variations are intended to be included within the scope of the present invention. All references cited are incorporated by reference into this application in their entirety.
Claims (11)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311585807.1A CN117820311A (en) | 2019-05-08 | 2019-05-08 | Preparation method of BTK inhibitor and intermediate thereof |
| CN201910382010.9A CN111909152B (en) | 2019-05-08 | 2019-05-08 | Preparation methods of BTK inhibitors and intermediates |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910382010.9A CN111909152B (en) | 2019-05-08 | 2019-05-08 | Preparation methods of BTK inhibitors and intermediates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311585807.1A Division CN117820311A (en) | 2019-05-08 | 2019-05-08 | Preparation method of BTK inhibitor and intermediate thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111909152A true CN111909152A (en) | 2020-11-10 |
| CN111909152B CN111909152B (en) | 2023-12-15 |
Family
ID=73241732
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910382010.9A Active CN111909152B (en) | 2019-05-08 | 2019-05-08 | Preparation methods of BTK inhibitors and intermediates |
| CN202311585807.1A Pending CN117820311A (en) | 2019-05-08 | 2019-05-08 | Preparation method of BTK inhibitor and intermediate thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311585807.1A Pending CN117820311A (en) | 2019-05-08 | 2019-05-08 | Preparation method of BTK inhibitor and intermediate thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN111909152B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104884458A (en) * | 2013-04-25 | 2015-09-02 | 百济神州有限公司 | Fused heterocyclic compounds as protein kinase inhibitors |
| WO2018033135A1 (en) * | 2016-08-19 | 2018-02-22 | Beigene, Ltd. | Use of a combination comprising a btk inhibitor for treating cancers |
| CN109563099A (en) * | 2016-08-16 | 2019-04-02 | 百济神州有限公司 | (S)-7-(1-Acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-A The crystal form of ]pyrimidine-3-carboxamide, its preparation and use |
-
2019
- 2019-05-08 CN CN201910382010.9A patent/CN111909152B/en active Active
- 2019-05-08 CN CN202311585807.1A patent/CN117820311A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104884458A (en) * | 2013-04-25 | 2015-09-02 | 百济神州有限公司 | Fused heterocyclic compounds as protein kinase inhibitors |
| CN109563099A (en) * | 2016-08-16 | 2019-04-02 | 百济神州有限公司 | (S)-7-(1-Acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-A The crystal form of ]pyrimidine-3-carboxamide, its preparation and use |
| WO2018033135A1 (en) * | 2016-08-19 | 2018-02-22 | Beigene, Ltd. | Use of a combination comprising a btk inhibitor for treating cancers |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117820311A (en) | 2024-04-05 |
| CN111909152B (en) | 2023-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6392436B2 (en) | Process for the preparation of substituted 5-fluoro-1H-pyrazolopyridines | |
| KR102625774B1 (en) | Synthesis of omecamtive mecarville | |
| WO2014016740A2 (en) | Improved process for the preparation of pralatrexate | |
| JP2003513974A (en) | Method for producing imidazolidinone αv-integrin antagonist and intermediate for production | |
| WO2024228133A1 (en) | Novel salts of tegoprazan and its polymorphs | |
| CN115850286A (en) | Weibeigelong intermediate and preparation method thereof | |
| JP7702968B2 (en) | Method for preparing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine carboxylates | |
| CN111909152A (en) | The preparation method of BTK inhibitor and its intermediate | |
| JPH03236359A (en) | Improvement of antiepileptic cyclic amino acid compound | |
| JP2013537534A (en) | Process for the preparation of compound OSI-906 | |
| JP7697933B2 (en) | Manufacturing process for 5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1H-1,2,4-triazol-3-amine | |
| US6979736B2 (en) | Process for the preparation of benazepril hydrochloride | |
| JP2003500333A (en) | Method for producing 4-[(2 ', 5'-diamino-6'-halogenpyrimidin-4'-yl) amino] cyclopent-2-enylmethanol | |
| KR101123281B1 (en) | Process for Preparing Substituted Benzamide Derivatives | |
| JP2013508418A (en) | Method for preparing 1- (4-((1R, 2S, 3R) -1,2,3,4-tetrahydroxybutyl) -1H-imidazol-2-yl) ethanone | |
| CN101066936B (en) | The refining method of ethylenedihydrazone | |
| CN118878427A (en) | A method for preparing ribotinib intermediate | |
| TW202313600A (en) | Preparation method of hepatitis B virus nucleocapsid inhibitor | |
| CN117658900A (en) | A kind of preparation method of tetrahydronaphthyridine compounds and its intermediates | |
| CN121405634A (en) | Synthesis method of 2-cyano-5- (p-tolyl) -1H-imidazole | |
| KR100929414B1 (en) | Process for the preparation of thromium chloride | |
| CN114907283A (en) | Preparation method of 2- (3, 5-dichlorophenyl) -benzoxazole-6-carboxylic acid | |
| CN120943782A (en) | A method for preparing a pyrazole ether compound | |
| KR20090010546A (en) | Method for preparing gabapentin and intermediates | |
| WO2019098551A1 (en) | Method for preparing intermediate compound for synthesizing pharmaceutical |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |